Combining NAT10 inhibition with direct targeting of the CD2BP2‐DT/YBX1 signaling pathway provides a multifaceted strategy to suppress tumor cell proliferation and survival, thereby potentially enhancing therapeutic efficacy. Here, YBX1 is linked to neoplasm.